A neurotrophic approach to treating hearing loss: Translation from animal models to clinical proof-of-concepta

• Published in: The Journal of the Acoustical Society of America 2022-06, Vol.151 (6), p.3937-3946
• Main Authors: Foster, Alan C., Szobota, Stephanie, Piu, Fabrice, Jacques, Bonnie E., Moore, David R., Sanchez, Victoria A., Anderson, Jeffery J.
• Format: Article
• Language: English
• ISSN: 0001-4966; 1520-8524
• DOI: 10.1121/10.0011510

Currently, there are no approved medicines available for the treatment of hearing loss. However, research over the past two decades has contributed to a growing understanding of the pathological mechanisms in the cochlea that result in hearing difficulties. The concept that a loss of the synapses connecting inner hair cells with the auditory nerve (cochlear synaptopathy) contributes to hearing loss has gained considerable attention. Both animal and human post-mortem studies support the idea that these synapses (ribbon synapses) are highly vulnerable to noise, ototoxicity, and the aging process. Their degeneration has been suggested as an important factor in the speech-in-noise difficulties commonly experienced by those suffering with hearing loss. Neurotrophins such as brain derived neurotrophic factor (BDNF) have the potential to restore these synapses and provide improved hearing function. OTO-413 is a sustained exposure formulation of BDNF suitable for intratympanic administration that in preclinical models has shown the ability to restore ribbon synapses and provide functional hearing benefit. A phase 1/2 clinical trial with OTO-413 has provided initial proof-of-concept for improved speech-in-noise hearing performance in subjects with hearing loss. Key considerations for the design of this clinical study, including aspects of the speech-in-noise assessments, are discussed.